Related references
Note: Only part of the references are listed.The future of CpG immunotherapy in cancer
Behnam Badie et al.
IMMUNOTHERAPY (2013)
The C-terminal decapeptide of prothymosin α is responsible for its stimulatory effect on the functions of human neutrophils in vitro
Pinelopi Samara et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2013)
Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy
Kyriaki Ioannou et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Dendritic Cell-Activating Vaccine Adjuvants Differ in the Ability to Elicit Antitumor Immunity Due to an Adjuvant-Specific Induction of Immunosuppressive Cells
Yushe Dang et al.
CLINICAL CANCER RESEARCH (2012)
Outlining novel scenarios for improved therapeutic cancer vaccines: the PANVAC paradigm
Constantin N. Baxevanis
EXPERT REVIEW OF VACCINES (2012)
Axillary lymph node coverage of tangent radiotherapy: Comparison of supine versus prone positioning
Gregory M. Thompson et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
Erika Hamilton et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Targeting pattern recognition receptors in cancer immunotherapy
Nadege Goutagny et al.
TARGETED ONCOLOGY (2012)
Trial Watch Experimental Toll-like receptor agonists for cancer therapy
Lorenzo Galluzzi et al.
ONCOIMMUNOLOGY (2012)
Trial watch FDA-approved Toll-like receptor agonists for cancer therapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2012)
TLR4 Engagement during TLR3-Induced Proinflammatory Signaling in Dendritic Cells Promotes IL-10-Mediated Suppression of Antitumor Immunity
Dusan Bogunovic et al.
CANCER RESEARCH (2011)
Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
Jitka Fucikova et al.
CANCER RESEARCH (2011)
Immune Adjuvant Efficacy of CpG Oligonucleotide in Cancer Treatment Is Founded Specifically upon TLR9 Function in Plasmacytoid Dendritic Cells
Stefan Nierkens et al.
CANCER RESEARCH (2011)
TLR3 as a Biomarker for the Therapeutic Efficacy of Double-stranded RNA in Breast Cancer
Bruno Salaun et al.
CANCER RESEARCH (2011)
Activation of Toll-like Receptor 5 on Breast Cancer Cells by Flagellin Suppresses Cell Proliferation and Tumor Growth
Zhenyu Cai et al.
CANCER RESEARCH (2011)
Heat-Shock Induction of Tumor-Derived Danger Signals Mediates Rapid Monocyte Differentiation into Clinically Effective Dendritic Cells
Raquel Aguilera et al.
CLINICAL CANCER RESEARCH (2011)
Impact of tumour volume on the potential efficacy of therapeutic vaccines
J. L. Gulley et al.
Current Oncology (2011)
MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLC.
P. Therasse et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Active immunization toward the MAGE-A3 antigen in patients with metastatic melanoma: Four-year follow-up results from a randomized phase II study (EORTC16032-18031).
W. Kruit et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma
Sofie Wilgenhof et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Type-I Polarized Dendritic Cells Loaded with Apoptotic Prostate Cancer Cells Are Potent Inducers of CD8+ T cells against Prostate Cancer Cells and Defined Prostate Cancer-Specific Epitopes
Eva Wieckowski et al.
PROSTATE (2011)
Toll-Like Receptors in Angiogenesis
Karsten Grote et al.
THESCIENTIFICWORLDJOURNAL (2011)
Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy
Gerty Schreibelt et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Toll-like Receptor 3-Mediated Suppression of TRAMP Prostate Cancer Shows the Critical Role of Type I Interferons in Tumor Immune Surveillance
Arnold I. Chin et al.
CANCER RESEARCH (2010)
Therapeutic Targeting of TLR9 Inhibits Cell Growth and Induces Apoptosis in Neuroblastoma
Chiara Brignole et al.
CANCER RESEARCH (2010)
Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors
Regina Berger et al.
CANCER SCIENCE (2010)
TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis
Manabu Taura et al.
CANCER SCIENCE (2010)
Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells
A. Weber et al.
CELL DEATH AND DIFFERENTIATION (2010)
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Joshua D. Brody et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Antitumor Activity and Immune Response Induction of a Dual Agonist of Toll-Like Receptors 7 and 8
Daqing Wang et al.
MOLECULAR CANCER THERAPEUTICS (2010)
A Novel Class of Immune-Stimulatory CpG Oligodeoxynucleotides Unifies High Potency in Type I Interferon Induction with Preferred Structural Properties
Ulrike Samulowitz et al.
OLIGONUCLEOTIDES (2010)
Prothymosin-α inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction
Arevik Mosoian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Sterile inflammation: sensing and reacting to damage
Grace Y. Chen et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Triggering of Toll-like Receptor 4 Expressed on Human Head and Neck Squamous Cell Carcinoma Promotes Tumor Development and Protects the Tumor from Immune Attack
Miroslaw J. Szczepanski et al.
CANCER RESEARCH (2009)
Double stranded-RNA-mediated activation of P21 gene induced apoptosis and cell cycle arrest in renal cell carcinoma
Jared M. Whitson et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Prothymosin α immunoactive carboxyl-terminal peptide TKKQKTDEDD stimulates lymphocyte reactions, induces dendritic cell maturation and adopts a β-sheet conformation in a sequence-specific manner
Margarita Skopeliti et al.
MOLECULAR IMMUNOLOGY (2009)
Novel Multi-Peptide Vaccination In Hla-A2+Hormone Sensitive Patients With Biochemical Relapse of Prostate Cancer
Susan Feyerabend et al.
PROSTATE (2009)
A clinical grade poly I:C-analogue (Ampligen (R)) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro
H. Navabi et al.
VACCINE (2009)
A cell biological view of Toll-like receptor function: regulation through compartmentalization
Gregory M. Barton et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway
Qun Jiang et al.
BMC CANCER (2008)
Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-α-dependent mechanism
Alessio Paone et al.
CARCINOGENESIS (2008)
CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans
W. Nicholas Haining et al.
CLINICAL CANCER RESEARCH (2008)
Twelve immunotherapy drugs that could cure cancers
Martin A. ‘Mac’ Cheever
IMMUNOLOGICAL REVIEWS (2008)
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant
Sylvia Adams et al.
JOURNAL OF IMMUNOLOGY (2008)
Immune Responses Detected in Urothelial Carcinoma Patients After Vaccination With NY-ESO-1 Protein Plus BCG and GM-CSF
Padmanee Sharma et al.
JOURNAL OF IMMUNOTHERAPY (2008)
The role of epithelial Toll-like receptor signaling in the pathogenesis of intestinal inflammation
Steven C. Gribar et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2008)
Immunological aspects of cancer chemotherapy
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2008)
How dying cells alert the immune system to danger
Hajime Kono et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy
Johan Vansteenkiste et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
FOXP3 regulates TLR10 expression in human T regulatory cells
Michael P. Bell et al.
JOURNAL OF IMMUNOLOGY (2007)
Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC)
J. Vansteenkiste et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Proteomic exploitation on prothymosin α-induced mononuclear cell activation
Margarita Skopeliti et al.
PROTEOMICS (2007)
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming
Danila Valmori et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Masquerader: High mobility group box-1 and cancer
Jessica E. Ellerman et al.
CLINICAL CANCER RESEARCH (2007)
Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro
Joanna M. Ilvesaro et al.
PROSTATE (2007)
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Holger Kanzler et al.
NATURE MEDICINE (2007)
Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling
Bo Huang et al.
CANCER RESEARCH (2007)
TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16
Uzma A. Hasan et al.
JOURNAL OF IMMUNOLOGY (2007)
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion
Brian J. Czerniecki et al.
CANCER RESEARCH (2007)
Role of toll-like receptors on human adipose-derived stromal cells
Hyun Hwa Cho et al.
STEM CELLS (2006)
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only
Sandra L. Giannini et al.
VACCINE (2006)
Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity
Melinda A. Merrell et al.
MOLECULAR CANCER RESEARCH (2006)
A new dendritic cell vaccine generated with interleukin-3 and interferon-β induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients
M Trakatelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer
MG Kelly et al.
CANCER RESEARCH (2006)
Vaccination with human papillomavirus type 16 E7 peptide with CpG oligonucleotides for prevention of tumor growth in mice
KB Gendron et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2006)
The low-toxicity versions of LPS, MPL® adjuvant and RC529, are efficient adjuvants for CD4+ T cells
BS Thompson et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2005)
Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells
G Napolitani et al.
NATURE IMMUNOLOGY (2005)
Toll-like receptors on tumor cells facilitate evasion of immune surveillance (Publication with Expression of Concern. See vol. 79, pg. 4305, 2019)
B Huang et al.
CANCER RESEARCH (2005)
Toll-like receptor signaling stimulates cell cycle entry and progression in fibroblasts
UA Hasan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Defining the antigen-specific T-Cell response to vaccination and poly(I:C)/TLR3 signaling -: Evidence of enhanced primary and memory CD8 T-Cell responses and antitumor immunity
ML Salem et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes
G Köllisch et al.
IMMUNOLOGY (2005)
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909
DE Speiser et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
TLR2 is expressed on activated T cells as a costimulatory receptor
M Komai-Koma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod
F Palamara et al.
JOURNAL OF IMMUNOLOGY (2004)
Apoptosis-related fragmentation, translocation, and properties of human prothymosin alpha
AG Evstafieva et al.
EXPERIMENTAL CELL RESEARCH (2003)
Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation
S Nair et al.
JOURNAL OF IMMUNOLOGY (2003)
Broad expression of Toll-like receptors in the human central nervous system
M Bsibsi et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2002)
Synergy between interleukin-2 and prothymosin α for the increased generation of cytotoxic T lymphocytes against autologous human carcinomas
IF Voutsas et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2000)
Share Paper
